Targeted pill offers new hope for Tough-to-Treat liver cancer
NCT ID NCT04353375
Summary
This study is testing an oral drug called HMPL-453 for people with advanced bile duct cancer inside the liver that has a specific genetic change (FGFR2 fusion/rearrangement) and has worsened after at least one prior treatment. The main goal is to see how well the drug shrinks tumors and how safe it is. Participants will take the pill daily for two weeks, then have a week off, repeating this three-week cycle.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.